A company emerging from the UPMC/University of Pittsburgh ecosystem, Generian entered an October 2026 research collaboration and exclusive option arrangement with Processa for an oral macrocyclic peptide FcRn antagonist.
United StatesFull profile →
Oral cyclic peptides · Companies
Matching companies load automatically. Browse 24 companies per page; expand filters to narrow the results.
Search & refine Filters update automatically
Disease tags identify mentions in recorded facts or pipeline text, not approved indications or a complete pipeline. Platform service providers may have no disease-specific tag.
79 matching companiesShowing 73–79 / 79
A cyclic peptide discovery company using trillion-scale peptide libraries, screening, and chemical optimization for internal programs and partnerships. Its website identifies oral peptide therapeutics as one potential application.
United StatesFull profile →
Provides cyclic and other complex peptide synthesis, noncanonical amino-acid modifications, peptide libraries, and in vitro oral-bioavailability screening. It is included as a discovery and development service provider.
Mainland ChinaFull profile →
Offers integrated structural biology, AI design, cyclic peptide synthesis, DMPK, and process-development capabilities. A September 2026 company article discusses oral cyclic peptide bioavailability, impurity control, and scale-up.
Mainland ChinaFull profile →
Holds exclusive development, manufacturing, and commercialization rights for linaclotide in Japan. It is included as a regional partner for an approved, locally acting oral disulfide-constrained peptide.
JapanFull profile →
Ironwood’s Q2 2026 filing confirms that Grand Life Sciences assumed AstraZeneca’s linaclotide development, manufacturing, and commercialization rights in China, including Hong Kong and Macau, in May 2026.
Mainland ChinaFull profile →
Aurinia’s Q3 2026 filing identifies Otsuka as the development and commercialization partner for oral voclosporin in Japan, the EU, the UK, and other specified territories, supported by a commercial supply arrangement.
JapanFull profile →
Coverage expands from sourced records; this database does not claim all biopharma companies.